Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Synthesis, Characterization, and Computational Modeling of N-(1-Ethoxyvinyl)pyridinium Triflates, an Unusual Class of Pyridinium Salts.

Shapiro JD, Sonberg JC, Schafer BC, Williams CC, Ferris HR, Reinheimer EW, Van Wynsberghe AW, Kriley CE, Majireck MM.

Molecules. 2018 Feb 14;23(2). pii: E413. doi: 10.3390/molecules23020413.

2.

Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and Phenethylamines.

Bennett JM, Shapiro JD, Choinski KN, Mei Y, Aulita SM, Dominguez GM, Majireck MM.

J Vis Exp. 2018 Jan 3;(131). doi: 10.3791/56848.

PMID:
29364238
3.

Quality and impact of eviQ Cancer Treatments Online (www.eviq.org.au): the medical oncologist's perspective.

Loke LPY, Chen TYT, Lewis CR, Ward RL, Rushton SA, Shapiro JD.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e203-e210. doi: 10.1111/ajco.12689. Epub 2017 May 25.

PMID:
28547805
4.

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

5.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
6.

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.

Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavlakis N, Gibbs P, Shapiro JD.

Expert Rev Anticancer Ther. 2016 May;16(5):557-71. doi: 10.1586/14737140.2016.1170594. Review.

PMID:
27010906
7.

Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.

Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD.

Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93. doi: 10.1586/14737140.2014.949678. Epub 2014 Aug 20. Review.

PMID:
25138900
8.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

9.

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group.

Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11.

10.

Financial incentives in cancer care and impact on prescribing practice.

Wong HL, Field KM, Shapiro JD, McKendrick JJ, Gibbs P.

J Clin Oncol. 2013 Aug 10;31(23):2973-4. doi: 10.1200/JCO.2013.49.5457. Epub 2013 Jul 15. No abstract available.

PMID:
23857965
11.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.

J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20.

PMID:
23690424
12.

Current opinion on optimal treatment for colorectal cancer.

Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD.

Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37. Review.

PMID:
23617351
13.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ.

Ann Oncol. 2013 Apr;24(4):953-60. doi: 10.1093/annonc/mds577. Epub 2012 Nov 8.

PMID:
23144444
14.

Management of advanced gastric cancer.

Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC.

Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):199-208; quiz 209. doi: 10.1586/egh.11.103. Review.

PMID:
22375525
15.

Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.

Price TJ, Tebbutt NC, Karapetis CS, Segelov E, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD.

Clin Colorectal Cancer. 2010 Jan;9(1):8-14. doi: 10.3816/CCC.2010.n.001. Review.

PMID:
20100683
16.

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.

Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ.

J Clin Oncol. 2009 Apr 10;27(11):1822-8. doi: 10.1200/JCO.2008.19.6048. Epub 2009 Mar 9.

PMID:
19273701
17.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

19.

Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies.

Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M.

Intern Med J. 2005 Apr;35(4):222-7.

PMID:
15836500
20.

Nurses' and consumers' understanding of and comfort with the Patient Self-determination Act.

Shapiro JD, Bowles K.

J Nurs Adm. 2002 Oct;32(10):503-8. Review. No abstract available.

PMID:
12394595
21.

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.

Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottrell J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH.

Cancer Chemother Pharmacol. 2001 Sep;48(3):215-22.

PMID:
11592343
22.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL.

J Clin Oncol. 2000 Feb;18(3):659-67.

PMID:
10653882
23.

A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.

Shapiro JD, Harold N, Takimoto C, Hamilton JM, Vaughn D, Chen A, Steinberg SM, Liewehr D, Allegra C, Monahan B, Lash A, Grollman F, Flemming D, Behan K, Johnston PG, Haller D, Quinn M, Morrison G, Grem JL.

Clin Cancer Res. 1999 Sep;5(9):2399-408.

24.

Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.

Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, Wolf M, Januszewicz H, Mitchell SV, Curran AC, Matthews JP, Bishop JF.

J Clin Oncol. 1998 Dec;16(12):3874-9.

PMID:
9850033
25.

More pharmaceutical company influence?

Shapiro JD, Phillips KA, Tannock IF.

Aust N Z J Med. 1998 Oct;28(5):675. No abstract available.

PMID:
9847969
26.

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.

Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.

Cancer. 1998 Nov 1;83(9):1980-8.

PMID:
9806657
27.

Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.

Shapiro JD, Millward MJ, Rischin D, Davison JD, Michael M, Francis PA, Ganju V, Toner GC.

Aust N Z J Med. 1997 Feb;27(1):40-4.

PMID:
9079252
28.

Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC.

Gynecol Oncol. 1996 Oct;63(1):89-93.

PMID:
8898175
29.
30.

The biomechanical effects of geometric configuration of bone-tendon-bone autografts in anterior cruciate ligament reconstruction.

Shapiro JD, Cohn BT, Jackson DW, Postak PD, Parker RD, Greenwald AS.

Arthroscopy. 1992;8(4):453-8.

PMID:
1466704
31.

Augmented external fixation of unstable distal radius fractures.

Seitz WH Jr, Froimson AI, Leb R, Shapiro JD.

J Hand Surg Am. 1991 Nov;16(6):1010-6.

PMID:
1748744
32.
33.

Angiomyoma in the hand.

Shapiro JD, Froimson AI.

Orthopedics. 1988 Dec;11(12):1709-10. Review.

PMID:
3068651
34.

Midazolam-sufentanil anaesthesia for phaeochromocytoma resection.

Shapiro JD, el-Ganzouri A, White PF, Ivankovich AD.

Can J Anaesth. 1988 Mar;35(2):190-4.

PMID:
2965627
35.

Intubating by sense, not dollars.

Shapiro JD.

Anesth Analg. 1987 Apr;66(4):373. No abstract available.

PMID:
2882710
36.

N2O has no place during oropharyngeal and laryngotracheal procedures.

Shapiro JD, el-Baz NM.

Anesthesiology. 1987 Mar;66(3):447-8. No abstract available.

PMID:
3826722

Supplemental Content

Loading ...
Support Center